argenx Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024 01:00 ET
|
argenx SE
$398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track to submit filing for pre-filled syringe (PFS) in...
argenx announces results of Annual General Meeting of Shareholders
May 07, 2024 17:30 ET
|
argenx SE
May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...
argenx to Present at BofA Securities 2024 Health Care Conference
May 07, 2024 01:00 ET
|
argenx SE
May 7, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
May 02, 2024 01:00 ET
|
argenx SE
May 2, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
April 16, 2024 01:00 ET
|
argenx SE
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first...
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
March 27, 2024 02:00 ET
|
argenx SE
RHO study supports proof-of-concept in primary Sjogren’s disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024, 7:00...
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
March 26, 2024 16:00 ET
|
argenx SE
March 26, 2024 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
March 26, 2024 02:00 ET
|
argenx SE
VYVGART® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP) Regulatory decision in Japan represents first global approval for VYVGART in ITP ...
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
March 07, 2024 16:01 ET
|
argenx SE
ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years Abstracts reflect real-world value and consistent efficacy and safety profile associated with...
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
February 29, 2024 01:00 ET
|
argenx SE
$374 million in fourth quarter and $1.2 billion in full year global net product sales sBLA for VYVGART® Hytrulo for CIDP accepted for priority review by FDA with PDUFA target action date of June...